Skip to main content

10 Result(s)

within O. van Tellingen Remove this filter Pharmacology/Toxicology Remove this filter

and

  1. No Access

    Article

    Cognitive impact of cytotoxic agents in mice

    Adjuvant chemotherapy is associated with changes in cognition in a subgroup of cancer patients. Chemotherapy is generally given as a combination of cytotoxic agents, which makes it hard to define the agent res...

    R. Seigers, M. Loos, O. Van Tellingen, W. Boogerd, A. B. Smit… in Psychopharmacology (2015)

  2. Article

    Open Access

    Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice

    The anticancer drug paclitaxel is formulated for i.v. administration in a mixture of Cremophor EL and ethanol. Its oral bioavailability is very low due to the action of P-glycoprotein in the gut wall and CYP45...

    Roos L. Oostendorp, T. Buckle, G. Lambert, J. S. Garrigue… in Investigational New Drugs (2011)

    Download PDF (217 KB) View Article

  3. No Access

    Article

    Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice

    Trabectedin is a novel anticancer drug active against soft tissue sarcomas. Trabectedin is a substrate for P-glycoprotein (P-gp), which is encoded by mdr1a/1b in rodents. Plasma and tissue distribution, and excre...

    J. H. Beumer, N. E. Franke, R. Tolboom, T. Buckle, H. Rosing… in Investigational New Drugs (2010)

  4. No Access

    Article

    A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling

    Abstract

    H. van den Bongard, R. Mathôt, O. van Tellingen… in Cancer Chemotherapy and Pharmacology (2002)

  5. No Access

    Article

    Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice

    Studies with CGP 41 251 (I), an N-benzoylstaurosporine derivative and PKC-α inhibitor, revealed that oral administration of 400 μg/day of the compound to wild type mice on four successive days reversed multi d...

    R. van Gijn, O. van Tellingen, E. Haverkate… in Investigational New Drugs (1999)

  6. No Access

    Article

    A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study

    We investigated the pharmacokinetic behavior of carzelesin in 31 patients receiving this drug by 10-min intravenous infusion in a Phase I clinical trial, which was conducted at institutions in Nijmegen (insti...

    O. van Tellingen, C. J. A. Punt, A. Awada… in Cancer Chemotherapy and Pharmacology (1998)

  7. No Access

    Article

    Oral Bioavailability of Low Dose (20mg) ‘Home-Made’ Etoposide Capsules

    The oral bioavailability of etoposide 20mg capsules, which were manufactured in our hospital pharmacy, was studied in 14 patients with various types of solid tumours. The presence of the lubricant colloidal si...

    Dr J. D. Jonkman-de Vries, V. M. M. Herben, O. van Tellingen… in Clinical Drug Investigation (1996)

  8. No Access

    Article

    Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion

     We investigated the pharmacokinetics of etoposide given to a patient suffering from multifocal liver metastases from an unknown primary tumor. The drug was given either by i.v. infusion or by hepatic arterial...

    O. van Tellingen, Maarten T. Kuck, L. T. Vlasveld… in Cancer Chemotherapy and Pharmacology (1996)

  9. No Access

    Article

    Pharmacokinetics of Etoposide after Oral and Intravenous Administration in Patients with Gastric Carcinoma

    The effects of the primary tumour in situ or of gastrectomy on the bioavailability and other pharmacokinetic parameters of etoposide, after oral administration of commercially available etoposide (Vepesid®, Brist...

    Dr J. D. Jonkman-de Vries, H. Rosing, O. van Tellingen… in Clinical Drug Investigation (1995)

  10. No Access

    Article

    Antibodies against cisplatin-modified DNA and cisplatin-modified (di) nucleotides

    Cytotoxic effects ofcis-diamminedichloroplatinum-(II) (cis-DDP) are thought to be mediated by binding to DNA. Studies on binding ofcis-DDP to cellular DNA rely heavily on the availability of specific antibodies. ...

    P. M. A. B. Terheggen, B. G. J. Floot… in Cancer Chemotherapy and Pharmacology (1991)